New Jersey Governor Phil Murphy; Hopewell Mayor Courtney Peters-Manning; John V. Oyler, Co-Founder, Chairman, and CEO of BeiGene; DPR Construction, IPS, and distinguished guests broke ground on BeiGene’s new manufacturing and clinical R&D center at the Princeton West Innovation Campus. The new innovation hub will focus on developing affordable medicines to improve cancer treatment outcomes. The initial phase of construction includes approximately 400,000-sq.-ft. of biologic pharmaceutical manufacturing space.
“At BeiGene, we are committed to not only delivering innovative and affordable medicines but also to upholding the highest standards of ethics and integrity, operational excellence, and environmental stewardship,” stated John V. Oyler, Co-Founder, Chairman and CEO of BeiGene.“This commitment applies to everything we do, including the development of BeiGene’s Hopewell project.
Through persistent innovation and challenging the status quo, IPS and our design partners, Van Note-Harvey Associates, Meyer Design, and Mainstay Engineering have worked interactively in developing a comprehensive execution approach focused on value to bring the Princeton West Campus project to reality. Additionally, DPR is self-performing select scopes of work. Leveraging our own forces helps alleviate workforce demands and the labor shortage across the AEC industry.
“We are providing counsel on design partners and consultants, phasing options for construction, and the equipment needed to build an immunotherapy facility in the US,” noted DPR’s Frank Haughey, Project Executive. “The Mid-Atlantic region of the US is a hotspot for pharmaceutical research and manufacturing, and BeiGene will have access to a deep talent pool and thriving business community to support their operation and future growth.”